Core Viewpoint - The major shareholder of Shandong Keyuan Pharmaceutical Co., Ltd., Mr. Wen Zehong, plans to reduce his shareholding by up to 3,248,700 shares, which accounts for 3.00% of the company's total share capital, through centralized bidding and block trading methods [1][2]. Group 1: Shareholder Information - Mr. Wen Zehong holds 8,400,000 shares, representing 7.76% of the company's total share capital [1]. - The planned reduction includes a maximum of 1,082,900 shares (1.00% of total share capital) through centralized bidding and up to 2,165,800 shares (2.00% of total share capital) through block trading [1][2]. Group 2: Reduction Plan Details - The reduction will occur within three months after the announcement, starting fifteen trading days from the date of the announcement [1][2]. - The total number of shares to be reduced through centralized bidding and block trading is capped at 3,248,700 shares [1][2]. Group 3: Shareholder Commitments - Mr. Wen made commitments regarding shareholding restrictions prior to the company's initial public offering, including a 36-month lock-up period for shares acquired before the IPO and a 12-month lock-up period for shares issued during the IPO [2][3]. - If Mr. Wen violates these commitments, any proceeds from unauthorized share reductions will belong to the company, and the company has the right to withhold dividends to recover the amounts [3][4].

证券代码：301281 证券简称：科源制药 公告编号：2025-040 山东科源制药股份有限公司 关于持股 5%以上股东股份减持计划的预披露公告 公司持股 5%以上股东问泽鸿先生保证向本公司提供的信息内容真实、准确 和完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 山东科源制药股份有限公司（以下简称"公司"）股东问泽鸿先生持有公司 股份8,400,000股（占公司总股本的7.76%），计划以集中竞价方式及大宗交易方 式减持公司股份不超过3,248,700股（不超过公司总股本的3.00%）。其中以集中 竞价交易方式减持公司股份不超过1,082,900股（占公司总股本的1.00%），以大 宗交易方式减持公司股份不超过2,165,800股（占公司总股本的2.00%）。问泽鸿 先生本次以集中竞价方式及大宗交易方式减持，将在本减持计划公告之日起十五 个交易日后的三个月内进行。 公司于近日收到股东问泽鸿先生出具的《关于股份减持计划的告知函》，现 将有关情况公告如下： | 股东名称 | 持股数量（股） | 占公司总股本 ...

Core Viewpoint - Koyuan Pharmaceutical is actively enhancing its market position through strategic acquisitions and international expansion efforts, aiming to build a competitive healthcare platform and increase profitability for shareholders [2][3][4]. Group 1: Stock Performance and Investor Engagement - On May 19, Koyuan Pharmaceutical's stock rose by 5.63%, closing at 32.62 CNY per share, with a trading volume of 5,707,140 shares and a turnover of 184,453,540 CNY, indicating high market activity [1]. - The company participated in an investor reception event organized by the Shandong Securities Regulatory Bureau, discussing its 2024 performance, governance, development strategy, and sustainability with investors [1]. Group 2: Acquisition of Hongjitang - Koyuan Pharmaceutical announced the acquisition of 99.42% of Hongjitang, aiming to integrate high-quality traditional Chinese medicine assets and create a competitive healthcare platform [2]. - The acquisition is expected to enhance the company's net profit attributable to shareholders, thereby maximizing shareholder value [2]. - Hongjitang, established in 1907 and recognized as a "Chinese Time-honored Brand," holds 150 drug licenses and has leading market shares in key products like Ejiao and Angong Niuhuang Wan [2]. Group 3: Global Expansion and Product Development - Koyuan Pharmaceutical focuses on the research, production, and sales of chemical raw materials and formulations, striving to become a leading domestic and internationally competitive pharmaceutical manufacturer [3]. - The company invested 37.63 million CNY in R&D in 2024, accounting for 8.12% of its revenue, with a 24.56% year-on-year increase in R&D personnel [3]. - The product portfolio includes various categories such as antidiabetic, anesthetic, cardiovascular, and psychiatric drugs, with all products certified by national GMP and several international regulatory bodies [3]. Group 4: International Market Development - Koyuan Pharmaceutical showcased its key products and solutions at two major international exhibitions, CPhI Japan and in-cosmetics Global in the Netherlands, to enhance global visibility and foster international collaborations [4]. - The company has made significant strides in its internationalization strategy, establishing a comprehensive marketing network across Europe, the Americas, and Asia-Pacific, and enhancing its core competitiveness and global influence [4].

Group 1: Company Overview and Objectives - The main purpose of the acquisition of Hongjitang is to integrate high-quality traditional Chinese medicine assets within the group, creating a competitive healthcare platform [1] - The acquisition aims to enrich the company's product portfolio, enhancing its risk resistance and market competitiveness [1] - The company seeks to leverage synergies to improve operational efficiency and profitability [1] Group 2: Share Issuance and Pricing - The share issuance price for acquiring assets is set at 16.73 yuan per share, which complies with regulations stating that the price must not be lower than 80% of the market reference price [2] - The market reference price is based on the average trading price of the company's shares over the 20 trading days prior to the board resolution announcement [2] - The board has approved the issuance price, and related directors will abstain from voting in the upcoming shareholders' meeting [2]

Group 1: Financial Performance - In 2024, the company achieved a revenue of 463.72 million CNY, a year-on-year increase of 3.60% [5] - The net profit attributable to shareholders was 60.45 million CNY, a decrease of 21.54% compared to the previous year [5] - Gross profit was 211.49 million CNY, with a decline of 2.94% [6] - Sales expenses increased by 21.69%, amounting to 13.75 million CNY [6] - Other income rose significantly by 289.38%, totaling 11.55 million CNY [6] Group 2: R&D Investment - The company invested 37.63 million CNY in R&D in 2024, representing 8.12% of its revenue [4] - R&D personnel increased by 24.56% compared to 2023 due to numerous ongoing projects [8] Group 3: Strategic Acquisitions - The acquisition of 99.42% of Hongjitang is expected to enhance the company's market competitiveness and product portfolio [3] - Hongjitang's integration will allow the company to extend its business into traditional Chinese medicine and health products [3] Group 4: Market Position and Product Development - The company focuses on chemical raw materials and formulations, with key products including Metformin, Glimepiride, and Isosorbide Mononitrate [4] - The company holds 31 raw material drug registration numbers and 43 chemical drug formulation approvals, with all products passing national GMP certification [14] - The global raw material drug market is projected to reach 236.7 billion USD in 2024, with a compound annual growth rate of 6.78% from 2021 to 2026 [13] Group 5: Future Growth Strategies - The company aims to strengthen existing products while rapidly introducing new varieties to create a second growth curve [10] - Plans to expand CDMO business and enhance collaboration with overseas clients are in place [10] - The company will focus on smart manufacturing and technological innovation to improve production efficiency [15]

山东科源制药股份有限公司 证券代码：301281 证券简称：科源制药 公告编号：2025-039 关于参加 2025 年山东辖区上市公司投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，山东科源制药股份有限公司（以下简称 "公司"）将参加由山东证监局、山东上市公司协会与深圳市全景网络有限公司 联合举办的"2025 年山东辖区上市公司投资者网上集体接待日活动"，现将相 关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景 路演APP,参与本次互动交流。活动时间为2025年5月15日（周四）15:00-16:30。 届时公司高管将在线就公司 2024 年度业绩、公司治理、发展战略、经营状况、 融资计划和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广 大投资者踊跃参与！ 特此公告！ 山东科源制药股份有限公司 董事会 2025年5月13日 ...

益分派方案一致。 间未超过两个月。 二、本次实施的权益分派方案 本公司2024年年度权益分派方案为：以公司现有总股本108,290,000股为基 数，向全体股东每10股派2.000000元人民币现金（含税；扣税后，通过深股通持 有股份的香港市场投资者、境外机构（含QFII、RQFII）以及持有首发前限售股 的个人和证券投资基金每10股派1.800000元；持有首发后限售股、股权激励限售 股及无限售流通股的个人股息红利税实行差别化税率征收，本公司暂不扣缴个人 所得税，待个人转让股票时，根据其持股期限计算应纳税额【注】；持有首发后 限售股、股权激励限售股及无限售流通股的证券投资基金所涉红利税，对香港投 资者持有基金份额部分按10%征收，对内地投资者持有基金份额部分实行差别化 税率征收）， 【注：根据先进先出的原则，以投资者证券账户为单位计算持股期限，持股 三、股权登记日与除权除息日 证券代码：301281 证券简称：科源制药 公告编号：2025-038 山东科源制药股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 山东科源制药股份有限公司（以下简称"公 ...

山东科源制药股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、股东大会审议通过2024年年度权益分派方案情况 1、山东科源制药股份有限公司于2025年5月9日召开了2024年年度股东大会， 审议通过《关于2024年度利润分配预案的议案》。公司2024年度利润分配预案为： 以实施权益分派股权登记日登记的总股本为基数，向全体股东每10股派发现金红 利2元（含税），不进行送红股、资本公积转增股本，剩余未分配利润结转以后 年度。在利润分配方案披露日至实施权益分派股权登记日期间，若公司总股本发 生变动，将按照分配比例不变的原则进行分配。 2、自利润分配方案披露至实施期间，公司股本总额未发生变化。 3、公司本次实施的权益分派方案与公司2024年年度股东大会审议通过的权 益分派方案一致。 4、此次权益分派实施距离股东大会审议通过2024年年度权益分派方案的时 间未超过两个月。 证券代码：301281 证券简称：科源制药 公告编号：2025-038 山东科源制药股份有限公司（以下简称"公司"）2024年年度权益分派方案 已获2 ...

证券代码：301281 证券简称：科源制药 公告编号：2025-037 山东科源制药股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、现场会议召开时间：2025年5月9日（星期五）15:00 2、现场会议召开地点：山东省济南市历城区经十东路30766号力诺智慧园山 东力诺制药有限公司第二会议室。 3、网络投票时间： 6、现场会议主持人：公司董事长高春坡先生 7、本次会议的召集、召开与表决程序符合《中华人民共和国公司法》《上 市公司股东会规则》《深圳证券交易所创业板股票上市规则》及《公司章程》等 有关法律、法规及规范性文件的规定。 （二）会议出席情况 1、出席会议股东的总体情况 本次股东大会出席的股东及股东代理人共75名，代表股份共计55,990,000 股，占公司有表决权股份总数的51.7038％。其中，中小投资者共72名，代表股 份共计12,352,000股，占 ...

德恒上海律师事务所 关于 山东科源制药股份有限公司 2024 年年度股东大会之 见证意见 致：山东科源制药股份有限公司 上海市东大名路 501 号上海白玉兰广场办公楼 23 楼 电话：021-5598 9888 传真：021-5598 9898 邮编：200080 德恒上海律师事务所 关于山东科源制药股份有限公司 2024 年年度股东大会之见证意见 德恒上海律师事务所 关于 山东科源制药股份有限公司 2024 年年度股东大会之 见证意见 德恒 02G20240142-00003 号 德恒上海律师事务所（以下简称"本所"）接受山东科源制药股份有限公司 （以下简称"公司"）的委托，指派孙竣锽律师、占俊律师列席公司于 2025 年 5 月 9 日召开的 2024 年年度股东大会（以下简称"本次股东大会"），就本次股东 大会召开的合法性进行见证并出具本见证意见。 本所见证律师依据本见证意见出具日前已经发生或存在的事实和《中华人民 共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称 "《证券法》"）、《上市公司股东会规则》（以下简称"《股东会规则》"）等现行 有效的法律、法规和规范性文件以及《 ...